US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting

STOCKHOLM — May 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients

STOCKHOLM — June 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM), have been presented at the ongoing 25[th] European Hematology Association meeting, EHA. The results support the NDA submission to the US Food and Drug Administration, FDA, for accelerated approval of melflufen. The Company is on track to submit the application to FDA by the end of Q2, 2020.Oncopeptides will

Oncopeptides hosts a virtual symposium at the 25[th] European Hematology Association Congress on Challenges in Managing Patients with Myeloma

STOCKHOLM — June 11, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13[th], focusing on the “Challenges in Managing Patients with Myeloma”. A panel of international experts will discuss disease assessment and treatment options in myeloma and share clinical experiences of managing patients that are difficult to treat.Due to the COVID-19 pandemic, the annual hematology meeting will be virtual. Oncopeptides has developed a virtual booth to demonstrate its commitment to the multiple myeloma community,

Oncopeptides announces new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting

STOCKHOLM — May 14, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA). The abstracts are now published online.Melflufen (melphalan flufenamide) is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in late stage clinical development for a potential treatment of patients with

New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

Stockholm - 16 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included in the “Novel strategies in multiple myeloma” session and was led by Professor Paul G. Richardson, Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute in Boston, Massachusetts, USA.The presentation will be available on the company webpage under: www.

New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Stockholm - 14 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study. On 16 June 2019, interim data from Oncopeptides’ ongoing, pivotal Phase 2 HORIZON trial will also be presented as an oral presentation by Professor Paul G. Richardson, Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper

Oncopeptides will host a Webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology (EHA) meeting

Stockholm – 13 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will make a review and update on the presented data from the European Hematology Meeting (EHA) on Monday, June 17, 2019, at. 09:00 (CET).It will be presented by CEO Jakob Lindberg and members of the Oncopeptide management team.    The conference call can also be followed via the link: https://tv.streamfabriken.com/2019-06-17-oncopeptides-press-conference.  Phone numbers for participants from:Sweden: +46 8 566 427 06Europe: +44 3333 009 030USA: +1 833 526 8384 For further

Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

Stockholm – May 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association (EHA) meeting (June 13-16, Amsterdam, Netherlands).Updated data from the Phase 2 HORIZON study evaluating melflufen for the treatment of relapsed/refractory multiple myeloma (RRMM) patients with no or limited remaining treatment options will be presented as an oral presentation by Professor Paul G. Richardson. Three poster presentations, one of which is from the ongoing Phase 1/2 ANCHOR

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA)

Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EHA congress in Stockholm. The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).The data are presented in a poster that can

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media